Assembly Biosciences, Inc. Business Combination, Consideration Transferred
Assembly Biosciences, Inc. (ASMB) reported Business Combination, Consideration Transferred of $29.82 million for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-05-08.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationConsiderationTransferred1 · last filed 2018-03-08
- Assembly Biosciences, Inc. business combination, consideration transferred for the quarter ending 2015-03-31 was $29.82M.
- Assembly Biosciences, Inc. business combination, consideration transferred for fiscal 2014 was $29.82M.
| Period end | Business Combination, Consideration Transferred 1 month | Business Combination, Consideration Transferred 3 month | Business Combination, Consideration Transferred 12 month |
|---|---|---|---|
| 2015-03-31 | $29.82M 10-Q · filed 2015-05-08 | ||
| 2014-12-31 | $29.82M 10-K · filed 2015-03-16 | ||
| 2014-07-31 | $29.82M 10-Q · filed 2014-11-17 | ||
| 2014-07-11 | $29.82M 10-K · filed 2018-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |